In the one SMARCA4 wild-type tumor (IGR-03) which showed concomitant ARID1A and ARID1B mutations, SMARCA2 expression was higher at the mRNA level (real-time RT-PCR) than in SMARCA4 mutated samples, and interpreted as ambiguous/low at the protein level (IHC). This evidence concerns the gene SMARCA2 and neoplasm.